Kunath Frank, Heidegger Isabel, Heck Matthias, Mayr Roman, Becker Christoph, Rausch Steffen
Klinik für Urologie und Kinderurologie, Klinikum Bayreuth GmbH, Bayreuth, Deutschland.
Fachgruppe Molekulare Urologie, Arbeitsgruppe urologische Forschung (AuF), Deutsche Gesellschaft für Urologie e. V., Düsseldorf, Deutschland.
Urologie. 2024 Sep;63(9):899-907. doi: 10.1007/s00120-024-02399-z. Epub 2024 Aug 6.
The rapid development of molecular medicine has opened up new perspectives for the diagnosis and treatment of urological tumors. Urology faces the challenge of effectively treating advanced cancer, especially in view of the genetic diversity of urological tumors. The molecular tumor board offers an innovative approach to identify targeted therapy options based on the individual genetic signatures of tumor cells or tumor microenvironment-based treatment options. In this article, the concept of the molecular tumor board in urology is presented using the example of prostate cancer. We discuss the principles, applications, and future prospects of this promising approach.
分子医学的快速发展为泌尿外科肿瘤的诊断和治疗开辟了新的前景。泌尿外科面临着有效治疗晚期癌症的挑战,尤其是考虑到泌尿外科肿瘤的基因多样性。分子肿瘤委员会提供了一种创新方法,可根据肿瘤细胞的个体基因特征或基于肿瘤微环境的治疗方案来确定靶向治疗方案。在本文中,以前列腺癌为例介绍了泌尿外科分子肿瘤委员会的概念。我们讨论了这种有前景的方法的原理、应用和未来前景。